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Chronic infection with Helicobacter pylori and non-steroidal anti-inflammatory drugs (NSAIDs) represent the two most important pathogenic factors in peptic ulcer disease [1] [2] [3] . Since eradication of H. pylori can cure peptic ulcer disease in the majority of H. pylori-associated peptic ulcers, increasingly more attention is given to prevention and therapy of NSAID-induced ulcers. This is ofparticularimportancesince NSAIDs are highly liable to produce severe ulcer complications such as massive gastrointestinal haemorrhage or perforation from complicated pepticulcers [4, 5] . It is now increasingly recognized that the occurrence of such complications is not restricted to the stomach and duodenum but can also result from ulcers localized in the small and large bowel [6] . Chronic administration of NSAIDs produces gastroduodenalmucosalerosions in 35--60% of patients, ulcerations in 10--25%, and severe gastrointestinal haemorrhage or perforation in < 1% [2, 4, 5] . In experimental and clinical conditions, indomethacin delays gastriculcerhealing [7, 8] . Among the mechanisms proposedfor delayed healing are: (a) inhibition of synthesis ofprostaglandins that are important for gastroduodenal mucosal defence [9] [10] [11] , (b) inhibition of epithelial cell proliferationin the ulcermargin that is critical for re-epithelialization of the ulcer crater [7, 12, 13] , (c) inhibition of angiogenesis that is essential for nutrientsupply in the ulcerbed [12] and, (d) inhibition of proliferation and function of myofibroblasts involvedin remodelling and contraction of the granulation tissue in the ulcerbed [12, 14] .
NSAIDs inhibit prostaglandin synthesis by the gastric mucosa and thromboxane production by platelets so impairing platelet aggregation. Within 90 rain of acute aspirin ingestion in humans, extensive intramueosal petechial haemorrhage becomes visible and this is, in part, related to promotion of bleeding from the antiplatelet actions of aspirin. With longer term ingestion, the number of erosions maydiminish, possibly by a process of adaptation [15] . However, erosions, petechiae and superficial ulcers are quite common in patients on long-term maintenance treatment with NSAIDs. Moreover, it is not established why a small proportion of patients develop chronic ulcersyetothersexhibit little or no mucosal damage.
The promotion of the concept of cytoprotection by the late Andr6 Robert [9] had fostered hopes that the use of co-prescribed mucosal protective agents would revolutionized the prevention of NSAID induced ulcers and supply the basis for novel ulcer therapy. The hopes were, however, only partially fulfilled. Thus, endoscopic studies haveshown that the prostaglandin analoguemisoprostol reduces the incidence of gastric and duodenal ulcers and the admission rate to hospital with ulcer complications [11] . Prostaglandins did not, however, revolutionize peptic ulcer therapy; they only exert modest ulcer healing at high acid-inhibitory doses [16] . Moreover, gastric biopsy lesions do not heal faster when diclofenac is combined with misoprostol treatment [17] . Profound acid suppression by high-dose proton pump inhibitors (PPIs) is, however, highly effective in the treatment of NSAID-induced gastroduodenal ulcerations both in man and experimental models [7, 12, 18, 19] . The advantage of the PPIs against prostanoids in ulcer prevention therapy is better tolerance, whereas theirlimitation is basedon the highercosts and possible undesirable side-effect of long-term anacidity (e.g. promotion of bacterial overgrowth with its theoretical carcinogenic potential).
NOVELNSAIDs AND THEIR TOXICITY IN ACUTE MODELS
Numerous strategies have been usedin recentyears to develop new anti-inflammatory and analgesic drugs that spare the gastrointestinal tract.
Several groups are attempting to developNSAIDs thatpredominantly inhibit effects on lipoxygenase or other particularly non-ulcerogenic pathways of lipid metabolism and/or which have antioxidant activity. Tebufelone, one ofthesecompounds, displaying both lipoxygenase and cyclo-oxgenase activity, has been shown to be gastroprotective in various models of NSAID-inducedinjury [20, 21] .
Another strategyfor developing gastrointestinal-sparing NSAIDs is the coupling of a nitric oxide-releasing moiety to a standard NSAID [22] [23] [24] [25] [26] [27] [28] [29] . The rationale behind this strategy is that the nitric oxide (NO) released from these derivatives will exert beneficial effects on the mucosa by maintaining gastrointestinal blood flow and inhibiting adherence and activation of white blood cells with the gastrointestinal mucosa [22, 23] . These promises are clearly fulfilled with regard to better acute tolerance and the results of one study suggest that experimental ulcer healing is not compromisedby this treatmentmodality [23] .
The most recent strategy is based on the recognition that cyclo-oxygenase (COX), the rate-limiting enzyme of prostaglandin (PG) synthesis exists in two forms, a constitutive COX-1 and an inducible COX-2, whereby the latter is activated in inflammatory exudates in rheumatic disease. By contrast PGs produced in normal gastric tissue are derived fromCOX-1 [30] . COX-2 inhibitors should thus theoretically be free ofgastrointestinal toxicity. The specific COX-2 inhibitor, L-745,337, has indeed been shown to produce minimal toxicity in acute gastric models, including in studies from our own laboratories [31] [32] [33] .
Hopes have been nourished for all the three groups of the above discussed novel NSAIDs, that these compounds will not compromise ulcerhealing and possibly even accelerate ulcerhealing.
STUDIES ON HEALINGOF CHRONIC EXPERIMENTAL ULCERS
We have performed a detailed analysis aimed at investigating how each ofthe three above-mentioned NSAIDs would interfere with the complex healing kinetics ofgastric ulcers. The studies were performed in a cryo-ulcer modelin the rat which allows a very precise analysis of healing through repeat endoscopy with exact measurements ofthe residual ulcersize [12] . In summary female Wistar rats with an initial body weight of 200-220 g were used. To permit regular endoscopic control ofthe healing process, a fistula cannula ofthe type generally used for gastric secretion studies (inner diameter 8 mm) was implanted in the forestomach under ether anaesthesia, three weeks prior to the onset of the study. After a 3-week recovery period, laparotomy was again performed in orderto induce an experimental ulcer with a cryoprobe (outer diameter 6.5 mm), which was placed on the gastric mucosa on the posterior wall ofthe central part ofthe corpus (duration 45 s) to generate standardized ulcers. The size ofthe ulcer was measured every 2-3 days using a video-endoscopic system. An arthroscope with a 30°oblique-viewing optical system (Stortz, Tuttlingen, FRG) was used in conjunction with an Olympus videocamera. For the examination, the rats were immobilized in Bollmann cages. Endoscopy required neither anaesthesia nor prior fasting. The stomach was irrigated via the fistula cannula to remove food particles. To record the size ofthe ulcer, a piece of calibrated paper (diameter 4 mm) was introduced via the fistula cannula and positioned next to the ulcer with the tip ofthe endoscope In two series of experiments, healing of cryo-ulcers was sequentially studied over a 15-day treatment period. The objectives of the first study were to analyse the effects of tebufelone and nitrofenac on ulcer healing in the above described rat ulcer model. The doses oftebufelone were either 1 or 10 mg/kg ig twice daily, and that for nitrofenac 3.75 mg/kg,ig twice daily. The comparators were placebo, omeprazole 40~tmol/kg sc, once daily, indomethacin 0.5 mg/kg sc, twice daily, diclofenac 2.5 mg/kg ig, twice daily, indomethacin 0.5 mg/kg sc twice daily + omeprazole 40 lunol/kg sc once daily. Rats were randomly treated with the above-mentioned medications for 15 days. . . |°l The objective ofthe second study was to examine the effects on ulcer healing ofthe COX-2 inhibitor, L-745,337. The doses used were 0.5 mg/kg, 2 mg/kg and 5 mg/kg, twice daily ig for 15 days. The same control treatments were applied as in the tebufelone/nitrofenac study. As shown in Figures 1 and 2 , all the three novelNSAIDs similarly delayed healing of the cryo-ulcers by a pattern of interference with the healing kinetics similar to that of indomethacin or diclofenac. By contrast, healing was accelerated during omeprazole monotherapy. The healing delay induced by the NSAIDs became substantial only in the second treatment week, while omeprazole accelerated healing predominantly in the first week. Concomitant treatment with omeprazole reversed the healing kinetics under NSAID treatment to the placebo values, thus still partly interfering with the speedpromoting effect which omeprazole exerts on healing.
In the second study,the dose-response relationship for the inhibition ofgastric ulcer healing rates fromdays 8-15 was compared between indomethacin, diclofenac and L-745,337 (n =26) The IDso values were 0.4 mg/kg, 0.8 mg/kg, and 1.7 mg/kg respectively (Figure 3 ). In search ofreasons for the interferenceon healing ofthe COX-2 inhibitor, L-745,337, microvessel density was quantified in the granulation tissue below the ulcer craterand compared with the known suppressive effects of conventional NSAIDs, such as indomethacin and diclofenac, on angiogenesis [12] . For all three compounds, a dosedependent inhibition ofangiogenesis was verified. The IDso values were 0.5 mg/kg for indomethacin, 1.0 mg/kg for diclofenac and 2.1 mg/kg for L-745,337. COX-2 immunoreactivity was not detected in glandular cells but in endothelial cells and many macrophages and fibroblasts in the submucosa and the granulation tissue involved in the healing process during days 3-15.
The result of our studies can be regarded as a further confirmation that increased tolerance ofthe gastric mucosa for thosenovel NSAIDs that are better tolerated by the intact gastric mucosa does not guarantee non-interference with ulcerhealing. During ulcer healing angiogenesis is a rate-limiting factor and the observation made in our study that L-745,337 interferes with angiogenesis in a similar way to conventional NSAIDs explains at least in part the ulcerhealing delay.There is increasing evidence from recent studies that COX-2, albeit largely absent in healthy mucosa is abundantly expressed at the edge ofhealing ulcers [34] [35] [36] . This is not really surprising since the COX-2 is abundant in inflammation such as in arthritic exudates. At the ulceredge COX-2 expression has been verified by immunohistochemical techniques in microvessels [36, 37] and macrophages. This has recently been confirmed with molecular biology techniques [37] by a Japanese group which has also confirmed in a mouse modelthat healing ofacetic acid ulcers is delayed by a COX-2 inhibitor. There is also an explanation for the conflicting results obtained with diclofenac coupled with an NO donor. In their study, Elliot et al. [23] supplied some data suggesting that this compound is not delaying healing ofulcers in the rat acetic acid model, but even slightly accerating ulcer cicatrization. Their study has, however, the limitationthat NSAID medication was limitedto the first week, in which all NSAIDs interfere only minimally with ulcer healing, as clearly outlined in our ulcer model, which allows complete analysis ofthe healing kinetics.
CONCLUSION
Our studies have dearly outlined that for prediction of gastric tolerance a clear distinction is necessary between cytoprotective and healing properties of drugs interfering with the cylco-oxygenase and lipoxygenase pathway of prostaglandin generation. These studies do not, however, exclude the possibility that these novel NSAIDs offer a therapeutic advantage due to better tolerance during short-term administration. Further studies are, however, necessary to determine whether this optimized gastrointestinal safety profile is maintained during long-term application. Caution appears to be particularly warranted against their uncritical application in patients suffering from pepticulcer disease.
